Johns Hopkins Perioperative Immunotherapy: 5 Breakthroughs for Mesothelioma Patients

Johns Hopkins researchers have achieved an 80% surgical completion rate in perioperative immunotherapy trials for mesothelioma, with median survival exceeding 28 months for resectable patients — a 40% improvement over historical surgery-plus-chemotherapy outcomes [3]. This approach, which delivers nivolumab (Opdivo) both before and after surgery, represents the most significant shift in operable mesothelioma treatment in over a decade.

Key facts about Johns Hopkins perioperative immunotherapy for mesothelioma?

1. Treatment center: Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland [9]
2. Approach: Neoadjuvant nivolumab before surgery plus adjuvant nivolumab after surgery [3]
3. Surgical success: 80% of trial patients completed planned surgical resection [3]
4. Median survival: Exceeds 28 months for resectable patients, compared to 16-20 months historically [3]
5. FDA foundation: Built on CheckMate 743 approval of nivolumab + ipilimumab for unresectable mesothelioma (October 2020) [2]
6. Drug cost: Nivolumab infusions cost approximately $13,000-$16,000 per cycle; clinical trials often cover study drug costs [15]
7. Eligibility: Early-stage pleural mesothelioma patients who are candidates for pleurectomy/decortication or extrapleural pneumonectomy [5]
8. Treatment schedule: Typically 3-4 neoadjuvant cycles over 6-8 weeks, then surgery, followed by up to 12 months adjuvant therapy [4]
9. Side effects: Grade 3-4 immune-related adverse events occur in approximately 15-20% of patients [13]
10. Active trials: Over 60 immunotherapy trials for mesothelioma are currently recruiting on ClinicalTrials.gov [10]

What is perioperative immunotherapy and why does it matter for mesothelioma?

Perioperative immunotherapy is a treatment strategy that administers immune checkpoint inhibitors in two phases: before surgery (neoadjuvant) and after surgery (adjuvant). For mesothelioma patients, this dual-phase approach addresses a fundamental limitation of surgery alone — microscopic cancer cells that survive even the most thorough resection [4].

"For twenty years, the standard approach was surgery plus chemotherapy, and we plateaued at median survivals of 16-20 months. Perioperative immunotherapy is the first strategy that has meaningfully moved that needle for operable patients."

— David Foster, Executive Director of Client Services, 18+ Years Mesothelioma Advocacy

The neoadjuvant phase serves two critical purposes. First, checkpoint inhibitors like nivolumab can shrink tumors before the surgeon operates, making resection more complete. Second, exposing the intact tumor to immunotherapy generates a robust immune response against cancer antigens — the immune system essentially learns to recognize mesothelioma cells while the primary tumor is still present [6].

The adjuvant phase capitalizes on this primed immune response. After surgery removes the bulk of visible disease, continuing nivolumab helps the immune system hunt down residual cancer cells that imaging cannot detect. This is particularly important in mesothelioma, where microscopic disease along the pleural lining frequently leads to recurrence after surgery alone [5].

Why is Johns Hopkins leading this mesothelioma research?

Johns Hopkins Sidney Kimmel Cancer Center has been at the forefront of checkpoint inhibitor research across multiple cancer types, and their mesothelioma program benefits from this deep institutional expertise [9]. The center's perioperative immunotherapy work for mesothelioma builds directly on their pioneering NEOSTAR platform trial, which demonstrated the safety and efficacy of neoadjuvant nivolumab in resectable lung cancer [6].

Dr. Patrick Forde, a thoracic oncologist at Johns Hopkins, has published extensively on neoadjuvant immunotherapy for thoracic malignancies. His research demonstrated that administering checkpoint inhibitors before surgery for non-small cell lung cancer produced major pathologic responses in 45% of patients [6]. This proof of concept provided the scientific foundation for extending the approach to mesothelioma.

"The Hopkins team isn't experimenting in the dark — they've systematically proven neoadjuvant immunotherapy works in lung cancer and are now applying those lessons to mesothelioma. That's exactly the kind of evidence-based progression we want to see."

— David Foster, Executive Director of Client Services, Host of MESO Podcast

Dr. Stephen Broderick, a thoracic surgeon at Johns Hopkins, brings the surgical expertise critical to the perioperative approach. His team has demonstrated that neoadjuvant immunotherapy does not increase surgical complications — a key concern when introducing a new treatment before major thoracic surgery [3]. The collaboration between medical oncology and surgery at Hopkins exemplifies the multidisciplinary model that produces the best mesothelioma outcomes.

Johns Hopkins is also one of the nation's designated specialized treatment centers for mesothelioma, with a patient volume that enables statistically meaningful clinical trials in this rare cancer [9].

How does perioperative immunotherapy compare to current standard treatment?

The current standard of care for operable mesothelioma typically involves neoadjuvant cisplatin-pemetrexed chemotherapy followed by surgery — either pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP). This approach has produced median overall survival of 16-20 months, a figure that has remained essentially unchanged for over a decade [5].

Perioperative immunotherapy with nivolumab differs from chemotherapy in several fundamental ways:

• Mechanism: Chemotherapy directly kills rapidly dividing cells (cancer and healthy); immunotherapy teaches the immune system to target cancer cells specifically [8]
• Duration of effect: Chemotherapy's anti-cancer activity stops when treatment ends; immunotherapy creates immune memory that can continue fighting cancer for months or years [1]
• Side effect profile: Chemotherapy causes nausea, neuropathy, and bone marrow suppression; immunotherapy's side effects are immune-related (thyroiditis, rash, colitis) but generally more manageable [13]
• Pathologic response: Perioperative immunotherapy trials have documented pathologic complete responses — no viable cancer in surgical specimens — which is extremely rare with neoadjuvant chemotherapy alone [3]

"When we see pathologic complete responses in mesothelioma surgical specimens after neoadjuvant immunotherapy, that's not just an incremental improvement — that's a fundamentally different outcome than anything we achieved with chemotherapy alone."

— David Foster, Executive Director of Client Services, 18+ Years Mesothelioma Advocacy

Some emerging trials are testing triple-modality approaches that combine neoadjuvant immunotherapy with chemotherapy followed by surgery, potentially leveraging the strengths of both systemic treatments [4]. The ATOMIC-meso and related trials represent this next evolution in multimodal therapy.

What results has the CheckMate 743 trial produced?

The CheckMate 743 trial provides the clinical foundation for all current mesothelioma immunotherapy research, including the perioperative approach at Johns Hopkins. This landmark phase III trial randomized 605 patients with unresectable pleural mesothelioma to receive either nivolumab plus ipilimumab or standard cisplatin-pemetrexed chemotherapy [1].

The results, published in The Lancet, demonstrated statistically significant survival improvements:

• Median overall survival: 18.1 months with immunotherapy vs. 14.1 months with chemotherapy [1]
• 3-year survival rate: 23% with immunotherapy vs. 15% with chemotherapy [1]
• Hazard ratio: 0.73, representing a 27% reduction in the risk of death [1]
• Non-epithelioid benefit: Patients with sarcomatoid or biphasic histology showed even greater benefit, with median survival of 18.1 vs. 8.8 months [1]

These results led to FDA approval of the nivolumab-ipilimumab combination for unresectable mesothelioma in October 2020 — the first new systemic therapy approved for mesothelioma since pemetrexed in 2004 [2]. The Hopkins perioperative trials now seek to extend these benefits to the roughly 20-25% of mesothelioma patients whose disease is detected early enough for surgical intervention [5].

What other immunotherapy trials are advancing mesothelioma treatment?

The Johns Hopkins perioperative program is part of a broader immunotherapy revolution in mesothelioma clinical trials. Several major studies are expanding the immunotherapy landscape:

BEAT-meso Trial

This phase III trial tested the combination of bevacizumab (an anti-angiogenic drug) with atezolizumab (a PD-L1 inhibitor) plus chemotherapy in frontline mesothelioma treatment. Published in The Lancet in 2024, the trial demonstrated that adding immunotherapy to chemotherapy plus bevacizumab improved progression-free survival [7].

ATOMIC-meso and Emerging Perioperative Trials

Multiple institutions beyond Johns Hopkins are now testing perioperative immunotherapy approaches. These trials explore different checkpoint inhibitors, combination regimens, and timing strategies to optimize the neoadjuvant-surgery-adjuvant sequence [10]. Over 60 active mesothelioma immunotherapy clinical trials are currently recruiting patients across the United States [10].

CAR T-Cell and Next-Generation Approaches

Beyond checkpoint inhibitors, researchers are developing CAR T-cell therapies that engineer a patient's own immune cells to attack mesothelioma. The NCI has committed over $10 million to this approach, which represents the next frontier beyond checkpoint inhibitors [14].

"We're seeing an unprecedented acceleration in mesothelioma immunotherapy research. Five years ago, we had one approved immunotherapy option. Today, there are over sixty active trials testing dozens of novel approaches — and perioperative strategies are among the most promising."

— David Foster, Executive Director of Client Services, Host of MESO Podcast

Who is eligible for perioperative immunotherapy at Johns Hopkins?

Not every mesothelioma patient qualifies for perioperative immunotherapy. The approach is specifically designed for patients whose disease can potentially be surgically resected. Eligibility criteria for Hopkins trials typically include [3, 9]:

• Histology: Confirmed malignant pleural mesothelioma (epithelioid or biphasic subtypes preferred)
• Stage: Clinical stage I-IIIA disease deemed potentially resectable by a thoracic surgeon
• Performance status: ECOG 0-1, meaning the patient is functional and able to carry out normal activities
• Organ function: Adequate pulmonary, cardiac, hepatic, and renal function to tolerate both immunotherapy and surgery
• No autoimmune conditions: Active autoimmune diseases requiring systemic immunosuppression are generally exclusionary
• No prior immunotherapy: Patients who have already received checkpoint inhibitors may not be eligible

A multidisciplinary tumor board at Johns Hopkins — including thoracic surgeons, medical oncologists, radiation oncologists, and pathologists — reviews each case to determine whether perioperative immunotherapy is appropriate [9]. Patients with peritoneal mesothelioma are typically treated with different protocols, including surgery combined with HIPEC.

What are the financial considerations for mesothelioma immunotherapy?

Immunotherapy for mesothelioma carries significant costs, but multiple pathways exist to manage the financial burden. Understanding these options is essential for patients and families navigating treatment decisions [15].

Treatment Costs

Nivolumab infusions cost approximately $13,000-$16,000 per cycle when used outside a clinical trial. A full perioperative course involving 3-4 neoadjuvant cycles plus up to 12 months of adjuvant therapy can total $150,000-$250,000 for the immunotherapy component alone, before accounting for surgery and hospitalization costs [13].

Clinical Trial Coverage

When patients enroll in clinical trials at Johns Hopkins or other institutions, the investigational drug is typically provided at no cost by the pharmaceutical sponsor. Research-related tests and procedures are also often covered by the trial. Standard-of-care costs — surgery, hospital stays, routine imaging — are billed to the patient's insurance as they would be regardless of trial participation [10].

Insurance and Assistance Programs

Most major insurers cover FDA-approved immunotherapy for mesothelioma (nivolumab + ipilimumab for unresectable disease). Bristol Myers Squibb offers patient assistance programs for Opdivo that can reduce out-of-pocket costs. The National Cancer Institute maintains a directory of financial assistance resources for cancer patients [15].

"Cost should never be the reason a mesothelioma patient misses out on immunotherapy. Between clinical trials that cover drug costs, manufacturer assistance programs, and the compensation available through asbestos trust funds and legal claims, there are real solutions. Our job as advocates is to connect patients to every resource available."

— David Foster, Executive Director of Client Services, 18+ Years Mesothelioma Advocacy

Legal Compensation and Treatment Funding

Mesothelioma patients may be entitled to compensation through asbestos trust funds, which hold over $30 billion in reserves for asbestos victims. Legal settlements and verdicts can also cover immunotherapy costs, lost wages, and quality-of-life damages. An experienced mesothelioma attorney can evaluate whether a patient qualifies for compensation that can fund advanced treatments like perioperative immunotherapy.

What does the future hold for mesothelioma immunotherapy?

The Johns Hopkins perioperative immunotherapy program represents one node in a rapidly expanding network of immunotherapy advances for mesothelioma. Several trends are shaping the future of treatment [5, 14]:

• Biomarker-guided selection: Researchers are identifying PD-L1 expression levels, tumor mutational burden, and other biomarkers that predict which patients will respond best to immunotherapy [11]
• Combination strategies: Trials testing immunotherapy plus chemotherapy plus surgery (triple-modality) are producing encouraging early results [7]
• Novel checkpoint targets: Beyond PD-1 and CTLA-4, investigators are targeting LAG-3, TIGIT, and other immune checkpoints that mesothelioma exploits [4]
• Cellular therapies: CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies offer personalized immune approaches currently in early-phase trials [14]
• Earlier intervention: As diagnostic tools improve, more patients may be identified at stages eligible for perioperative approaches [8]

Mesothelioma remains a rare and aggressive cancer, with approximately 3,000 new diagnoses annually in the United States [8]. However, the immunotherapy advances driven by programs at Johns Hopkins and peer institutions are transforming the prognosis for patients who are diagnosed early enough to benefit from surgical intervention.

Patients diagnosed with mesothelioma should consult a comprehensive immunotherapy guide and discuss clinical trial eligibility with their oncologist. A free case assessment can also help determine whether legal compensation may be available to cover treatment costs.

Frequently asked questions about Johns Hopkins mesothelioma immunotherapy?

What is perioperative immunotherapy for mesothelioma?

Perioperative immunotherapy is a treatment strategy that combines checkpoint inhibitor drugs like nivolumab (Opdivo) both before surgery (neoadjuvant) and after surgery (adjuvant). The neoadjuvant phase aims to shrink tumors and activate the immune system before the operation, while the adjuvant phase targets residual cancer cells that surgery may have missed. Johns Hopkins trials have demonstrated that this combined approach can achieve 80% surgical completion rates and median survival exceeding 28 months [3].

Who qualifies for the Johns Hopkins perioperative immunotherapy trial?

Candidates typically include patients with early-stage pleural mesothelioma who are surgical candidates for pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP). Patients must have adequate organ function, an ECOG performance status of 0-1, and no active autoimmune diseases requiring systemic immunosuppression. A multidisciplinary team at Johns Hopkins evaluates each case individually [9].

How does perioperative immunotherapy compare to standard chemotherapy before surgery?

Standard neoadjuvant treatment uses cisplatin-pemetrexed chemotherapy to shrink tumors before surgery. Perioperative immunotherapy with nivolumab works differently by activating the patient's immune system to attack cancer cells. Early data suggests immunotherapy may produce more durable responses because the immune system continues fighting residual cancer after surgery, whereas chemotherapy effects end when treatment stops [1, 4]. Historical median survival with surgery plus chemotherapy is 16-20 months, compared to 28+ months in perioperative immunotherapy trials [3].

What are the side effects of perioperative immunotherapy for mesothelioma?

Perioperative immunotherapy side effects differ from chemotherapy and include immune-related adverse events such as fatigue, skin rash, thyroid dysfunction, pneumonitis, and colitis. In clinical trials, grade 3-4 immune-related adverse events occur in approximately 15-20% of patients. Most side effects are manageable with corticosteroids and immunosuppressive medications, and they rarely delay or prevent planned surgery [13].

Does insurance cover perioperative immunotherapy for mesothelioma?

Insurance coverage varies. Nivolumab is FDA-approved for unresectable mesothelioma in combination with ipilimumab, but perioperative use is investigational. Clinical trial enrollment typically covers the study drug at no cost. Standard-of-care costs like surgery and hospital stays are usually billed to insurance. Patient assistance programs from Bristol Myers Squibb and compensation through asbestos trust funds can help with out-of-pocket costs [15].

What survival improvements does perioperative immunotherapy offer?

Early results from perioperative immunotherapy trials show median survival exceeding 28 months for resectable pleural mesothelioma patients, compared to historical medians of 16-20 months with surgery plus chemotherapy. Some patients have achieved pathologic complete responses, meaning no viable cancer cells remain in surgical specimens [3]. The CheckMate 743 trial demonstrated 18.1-month median survival for immunotherapy in unresectable disease, with 23% of patients alive at three years [1].

How do I enroll in a mesothelioma immunotherapy clinical trial?

Patients can contact Johns Hopkins Sidney Kimmel Cancer Center directly, search ClinicalTrials.gov for active mesothelioma immunotherapy studies, or work with a mesothelioma patient advocate who can match them with appropriate trials. Eligibility screening typically involves imaging, blood work, and pathology review [10]. A free case assessment can also help connect patients with trial resources and determine compensation eligibility.

References

1. CheckMate 743: Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma. The Lancet, 2021. View Source
2. FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma. U.S. Food and Drug Administration, 2020. View Source
3. Neoadjuvant Nivolumab in Resectable Malignant Pleural Mesothelioma. Johns Hopkins Sidney Kimmel Cancer Center, 2025. View Source
4. Perioperative Immunotherapy for Solid Tumors: Current Evidence and Future Directions. Journal of Clinical Oncology, 2024. View Source
5. Malignant Pleural Mesothelioma Treatment (PDQ). National Cancer Institute, 2025. View Source
6. Neoadjuvant Checkpoint Blockade for Resectable Non-Small Cell Lung Cancer (NEOSTAR Trial). New England Journal of Medicine, 2022. View Source
7. BEAT-meso Trial: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma. The Lancet, 2024. View Source
8. Mesothelioma - Malignant. National Cancer Institute, 2025. View Source
9. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Mesothelioma. Johns Hopkins Medicine, 2025. View Source
10. Mesothelioma Immunotherapy Clinical Trials. ClinicalTrials.gov, 2026. View Source
11. Checkpoint Inhibitor Immunotherapy and Its Growing Role in Mesothelioma Treatment. Annals of Thoracic Surgery, 2025.
12. Pleurectomy/Decortication vs Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2024.
13. Nivolumab (Opdivo) Prescribing Information. U.S. Food and Drug Administration, 2023. View Source
14. Multimodal Treatment Approaches for Malignant Pleural Mesothelioma. National Cancer Institute, 2025. View Source
15. Patient Financial Assistance Programs for Cancer Treatment. National Cancer Institute, 2025. View Source